Clinical use of H1 MR spectroscopy in assessment of relapsing remitting and secondary progressive multiple sclerosis  by Abd El-Rahman, Hossam M. et al.
The Egyptian Journal of Radiology and Nuclear Medicine (2012) 43, 257–264Egyptian Society of Radiology and Nuclear Medicine
The Egyptian Journal of Radiology andNuclearMedicine
www.elsevier.com/locate/ejrnm
www.sciencedirect.comORIGINAL ARTICLEClinical use of H1 MR spectroscopy in assessment
of relapsing remitting and secondary progressive
multiple sclerosisHossam M. Abd El-Rahman a, Doaa I. Hasan a,*, Heba A. Selim b,
Sbah M. Lotﬁ b, Wael M. Elsayed ba Department of Radio-Diagnosis, Zagazig University, Egypt
b Department of Neurology, Zagazig University, EgyptReceived 30 September 2011; accepted 28 December 2011
Available online 9 February 2012*
Sh
E-
El
ho
D
03
M
Pe
N
do
OpKEYWORDS
Multiple sclerosis;
RRMS;
SPMS;
EDSS;
Brain metabolites;
H1 MR spectroscopyCorresponding author. Ad
arkia, Egypt. Tel.: +20 1136
mail addresses: hossamma
-Rahman), dididodge@yaho
tmail.com (H.A. Selim), Ahm
rwaelneuro@yahoo.com (W.
78-603X  2012 Egyptian
edicine. Production and host
er review under responsibility
uclear Medicine.
i:10.1016/j.ejrnm.2011.12.009
Production and h
en access under CC BY-NC-ND lidress: Z
94905.
nsour72@
o.com (D
ed.nade
M. Elsay
Society
ing by El
of Egyp
osting by E
cense.Abstract Background: Conventional MRI has a limited ability to provide speciﬁc information
about axonal pathology in MS, recently, MRI spectroscopy used for assessment of the axonal loss
even in normal appearing white matter.
Objective: To assess the axonal degeneration in plaques and normal appearing white matter in
patients with relapsing remitting MS and secondary progressive MS, and correlate their clinical dis-
ability using expanded disability status scale (EDSS) score with H1 MRS abnormalities.
Patients and methods: Thirty-two MS patients (20 RRMS, 12 SPMS) and 20 controls were sub-
jected to thorough history taking, clinical examination with special attention to: age at ﬁrst symp-
toms, disease duration and the EDSS score. MRS was performed in order to map N-acetylaspartate
(NAA), choline (Cho) and creatine (Cr).agazig University Hospital,
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258 H.M. Abd El-Rahman et al.Results: In SPMS, the NAA/Cr ratio and absolute concentrations for NAA in MS plaques and
NAWM were signiﬁcantly reduced compared to RRMS and to controls, also, signiﬁcant relation
with this metabolite values and clinical disability using EDSS score.
Conclusion: In SPMS patients group there were signiﬁcant reduction in the levels of NAA in both
plaques and NAWM compared to RRMS and control groups, moreover signiﬁcant correlation of
NAA reduction in the plaques of both groups related to clinical disability and disease progression.
 2012 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Multiple sclerosis (MS), one of the most common causes of
neurological disability in young adults, is an inﬂammatory
demyelinating and degenerative autoimmune disorder of the
central nervous system (CNS) (1).
Several patterns of the disease have been delineated. The
most common classiﬁcation includes benign (20%), relapsing
remitting MS (RRMS) (25%), secondary progressive MS
(SPMS) (40%), primary progressive and other forms (15%)
(2).
Although conventional MRI is sensitive in detecting the le-
sions of multiple sclerosis, it disclosed neither demyelination
nor axon loss itself (3), also, the amount of white matter
involvement seen on FLAIR and T2-weighted MR images is
poorly related to clinical disability (4). Proton magnetic reso-
nance spectroscopy (MRS) is a nuclear magnetic resonance
technique which has the potential to detect axon loss, and pro-
vide tissue metabolic information in vivo (5). Hallmark of all
subtypes of MS are focal lesions that are distinguished by their
content of activated macrophages and T cells, edema, demye-
lination, and axonal transection (6), each of these histopathol-
ogies appears hyperintense on T2-weighted MRI. The white
matter, which appears normal on gross pathology, shows
mostly astroglial hypertrophy and to a much lesser extent
inﬂammatory inﬁltrate, demyelination, or axonal loss (7).
MRS studies (5,8,9) comparing lesions and normal appear-
ing white matter (NAWM) in RRMS and SPMS measured
the following metabolites: N-acetyl aspartate (NAA), which
has been suggested to be a marker for neuron viability and
axonal density in the brain (10), creatine (Cr) which repre-
sents a combination of creatine and phosphocreatine, a mar-
ker of gliosis (11,12) and choline (Cho) thought to be a
marker associated with membrane phospholipids, in which
greater concentrations of choline are highly indicative of ac-
tive inﬂammatory disease (13). H1 MR studies of RRMS
show reduced NAA/Cr in T2-intense lesions and normal
appearing white matter (10).
Presumably, these metabolic changes in normal appearing
white matter reﬂect microscopic disease and decreased NAA/
Cr in lesions and normal appearing white matter of RRMS
probably reﬂects decreased NAA and increased Cr (11,14).
NAA is shown to be similarly reduced in MRI lesions of SPMS
and RRMS and NAA is also decreased in normal appearing
white matter in SPMS (8).
Previous studies have reported that Cr is increased in
RRMS normal appearing white matter compared to white
matter of SPMS. The increased Cr has been attributed to
microscopic disease; most likely gliosis. The reduction in
NAA is the reﬂection of more disability as in SPMS group.
If increase in Cr in RRMS normal appearing white matterand focal lesions relative to SPMS would be consistent with
the notion that sustained progression of disability reﬂects glio-
sis in addition to inﬂammation and axonal loss (8,15).
The aim of this study was to assess the role of H1 MRS in
the extent of axonal degeneration in NAWM in patients with
RRMS and SPMS, and, to correlate their clinical data with
H1 MRS abnormalities.2. Patients and methods
The present study was carried out on 32 multiple sclerosis pa-
tients from June 2009 to June 2011, who met the criteria of
clinically deﬁnite MS according to Poser et al. (16) deﬁnitions,
selected from Neurology Department, Zagazig University
Hospitals, 20 patients with RRMS and 12 patients with SPMS.
Twenty healthy volunteers with similar age and gender distri-
bution (control group) were included in this study. The study
was approved by the Ethical Committee of our Faculty and in-
formed written consent was obtained from patients and
controls.
All patients were subjected to:
I. Full general and neurological examination with special
attention to:
(1) The duration of the disease (i.e., the interval bet-
ween the date of ﬁrst symptom and the date of
examination (measured in years)).
(2) Patient’s age at ﬁrst symptoms (625 years or
>25 years).
(3) The expanded disability status scale (EDSS)
score(17): Patients with RRMS were divided according to
EDSS score to:– Mild disability 62.5.
– Moderate to severe disability >2.5. Patients with SPMS, few of them had mild dis-
ability and these patients were therefore recl-
assiﬁed with those with an EDSS score 65.5
and an EDSS score greater than 5.5 to provide
a homogenous division.II. Radiological evaluation was performed in Zagazig Uni-
versity Radiology MRI Unit: MR images were acquired
using a 1.5T Philips (Achieva, class IIa) using a standard
quadrature head coil. The following sequences were col-
lected from each patient and control during a single
session:
* T1 weighted Sagittal localizer (TE = 10 ms,
TR = 500 ms).
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matrix = 256 · 128).
* Axial T2 (TR = 6000, TE = 100 ms, FOV= 22 cm,
thickness = 5 mm, matrix = 256 · 128).
* Axial and Sagittal FLAIR(ﬂuid-attenuation inversion
recovery) (TR = 800, TE = 147 ms, FOV = 22 cm,
thickness = 5 mm, matrix = 256 · 128).* Three dimensional proton spectroscopic imaging was
performed with a repetition time (TR) of 1500 ms
and an echo time (TE) of 135 ms using single voxel
MRS. The number of peaks ﬁtted included the che-
mical shift ranges:
 N-acetylasparate (NAA) at 2.0 ppm.
 Creatine/phosphocreatine (Cr) at 3.0 ppm.
 Choline compounds (Cho) at 3.2 ppm.
 Myo-inositol (mI) at 3.5 ppm.
 Glutamine–glutamate–GABA complex (Glx) bet-
ween 2.1 and 2.5 ppm.
 Lactate (Lac) 1.35 ppm.
 Free lipids (Lip): wide resonance at 1.3 and
0.9 ppm.
Using a standardized post-processing protocol, the raw data
were thus processed automatically, allowing for operator-inde-
pendent quantiﬁcations. Metabolite concentrations were deter-
mined from peak areas. As many literature (10,13) the peak
values of N-acetylaspartate (NAA), choline (Cho) and creatine
(Cr) and relative ratios of these metabolites were calculated.
2.1. Image interpretations
These were analyzed for a variety of radiographic features:
 FLAIR-T2WIs for detection of the location and lesion
actual size.
 The ROIs within MS plaques and within normal white
matter.
 The ROIs within normal white matter of control group.
 The ROIs may be located anterior or posterior to centrum
semiovale.
2.2. Statistical analysis
We performed all statistical analyses with the SPSS version 11,
P< 0.05 was considered statistically signiﬁcant.
Group means were compared using unpaired Student’s t-
test and one way analysis of variance (ANOVA) test. Pearson
correlation coefﬁcient (r) was calculated to assess the correla-
tion between quantitative data (18).
The signiﬁcance of the NAWM metabolite concentrations
between both patient groups and the healthy controls was as-
sessed by the Mann Whitney test.
3. Results
Demographic and clinical data of our patients were illustrated
in Table 1: This study included two groups of patients with
MS, divided according to the course of the disease into:
The ﬁrst group: 20 patients with RRMS, seven males, 13 fe-
males. Their mean age was 38 ± 8.9 years, the mean diseaseduration was 5.8 ± 2.3 years, EDSS score had a mean of
1.65 ± 2.1 and the mean age at ﬁrst symptom was
29.8 ± 10.1 years.
The second group: 12 patients with SPMS, ﬁve males, seven
females, their mean age was 43.1 ± 11.1, themean disease dura-
tion was 10.5 ± 5.8, EDSS score had amean of 4.95 ± 1.85 and
the mean age at ﬁrst symptom was 33 ± 11.2 years.
The control group: 20 volunteers, 10 males and 10 females,
with mean age 42.1 ± 10.5 years.
MRI ﬁndings in our patients were listed in Table 2,
supra-tentorial lesions present in 28 patients, eight of themwere
periventricular and ranging from 0.4 to 2 cm, while 20 lesions
were cortical and subcortical and ranging from0.2 to 1 cm.Only
four patients had infra-tentorial lesions ranging from 0.4 to
2 cm.
In SPMS patients we found that there was a signiﬁcant
reduction of NAA in MS plaques (Fig. 1) which were
(3.97±1.47).
When comparing neurometabolites, the level of NAA in
NAWM of the SPMS group, there was a signiﬁcant reduction
of NAA (Fig. 2) comparing with RRMS and controls. NAA
(6.5±1.9 versus 7.48±2.1 and 8.9±1.85, respectively,
p 6 0.05) as shown in Table 3.
The other ﬁnding noted in this study was the signiﬁcant
reduction in both NAA/Cr and NAA/Cho ratios in SSPM pla-
ques and NAWM compared to RRMS and controls (in SPMS
were 1.68 ± 1.3 and 1.38 ± 0.65 versus 3.74 ± 1.4, 3.1 ± 1.1
and 4.1 ± 1.62, 3.2 ± 1.2 in RRMS and controls, respectively,
p 6 0.05).
Increased Cr and Cho in the RRMS (Fig. 3) but they were
not statistically signiﬁcant compared to the SPMS and
controls.
When we correlated NAA/Cho ratio and age at ﬁrst symp-
toms, we found that there was a signiﬁcant reduction in the ra-
tios in patients with RRMS whose age at ﬁrst symptom was
>25 years, but in patients with SPMS there was a signiﬁcant
reduction in ratios in patients whose age at ﬁrst symptoms
was <25 as shown in Table 4. Also, there is a positive signif-
icant relation between longer disease duration of both groups
and the reduction of metabolite ratio.
Regarding the relation between MRS ﬁndings (NAA/Cho
ratio) and clinical disability using EDSS score we found that
there is negative signiﬁcant correlation between patients with
RRMS (EDSS score 62.5) (B-coefﬁcient = 0.46, SE =
0.06, P 6 0.05*), also, those with moderate to severe disability
(in SPMS, EDSS score >5.5) (B-coefﬁcient = 0.46,
SE = 0.06, P 6 0.05*) (Table 5).4. Discussion
Advanced MRI techniques including MR spectroscopy have
been shown to provide information about structural and bio-
chemical alterations within and outside MS WM lesions
(19,20). Also, MRS has proven useful in assessing neuronal
damage like axonal loss, as NAA is exclusively localized in
the neuronal compartment (21,22). As, axonal and neuronal
damages have long been implicated as a main cause of irrevers-
ible MS disability (23). NAA is almost exclusive to neurons
and correlated better with clinical disability than other imaging
metrics (24,25), as it is an early event that occurs before the
formation of MRI visible lesions (5).
Table 1 Clinical data of the two groups as classiﬁed by clinical disease course, and control group.
RRMS (n= 20) SPMS (n= 12) Control (n= 20)
Age (years) 39 ± 8.9 43 ± 11.1 42.1 ± 10.5
M/F 7/13 5/7 10/10
Disease duration 5.8 ± 2.3 10.5 ± 5.8 –
EDSS score 1.65 ± 2.1 4.95 ± 1.85* –
Age at ﬁrst symptom (years) 29.8 ± 10.1 32 ± 11.0 –
* Statistically signiﬁcant relationships, P 6 0.05.
Table 2 Imaging ﬁnding in our patients by conventional MRI technique.
Location
(No.)
Size in FLAIR
(No.)
MR appearance
Supra-
tentorial (28)
04–2 cm (8) Oval and linear lesions around the periventricular area, perpendicular
to the long axis of the ventricles
0.2–1 cm (20) Rounded small lesions in the cortical and subcortical regions
Infra-tentorial
(4)
2–3 cm (2) Ill-deﬁned lesions in parietal white matter
0.4–2 cm (2) Oval and rounded shape cerebellar peduncles and brain stem lesions
Figure 1 MR images of a 34-year-old male SPMS patient. (A) Axial FLAIR. (B) Coronal T2 W. (C) Sagittal T2W showing multiple
periventricular and subcortical MS plaques in all images, the red rectangles indicate the volume of interest (VOI) for MR spectroscopy.
(D) Proton MR spectra of this SPMS patient showing reduction of N-acetylaspartate (NAA), choline (Cho) and elevated creatine (Cr)
peaks.
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patient groups, using EDSS score; also we analyzed NAA,
Cr and Cho levels of MS plaques and NAWM of 32 MS
patients and 20 controls.
In the present study, negative signiﬁcant correlation be-
tween MRS ﬁnding and age at ﬁrst symptom, disease duration,this ﬁnding is in agreement with previous studies (26–29). In
the current study, we found a positive signiﬁcant correlation
between MRS ﬁndings and clinical score using EDSS score
(0.46, P 6 0.05*), in accordance with ﬁndings reported by
Adalsteinsson et al. (30). MRS seems to be a potential surro-
gate marker of disease progression (26). In contrast to our
Figure 2 MR images of a 28-year-old male patient with SPMS. (A) Axial FLAIR. (B) Coronal T2WI. (C) Sagittal T1WI showing
multiple periventricular MS plaques, the red rectangles indicate the volume of interest (VOI) for MR spectroscopy. (E) Axial FLAIR. (F)
Coronal T2WI. (G) Sagittal T1WI of the same patient where the red rectangles in the normal white matter area in the Rt. side. (D and H)
proton MR spectra of this SPMS patient showing reduction of N-acetylaspartate (NAA), choline (Cho) and elevated creatine (Cr) peaks in
plaque as compared with the normal appearing white matter of the other cerebral hemisphere.
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Table 3 Comparison between the MRS different metabolites values in MS plaques of both RRMS and SPMS, contralateral normal
appearing white matter and healthy controls white matter.
NAA, X ± SD Cr, X ± SD Cho, X ± SD NAA/Cr, X ± SD NAA/Cho, X ± SD
RRMS (n= 20)
 MSP 5.48 ± 2.3 4.06 ± 1.8 2.5 ± 0.5 3.74 ± 1.4 3.1 ± 1.1
 NAWM 7.48 ± 2.1 5.1 ± 2.1 2.48 ± 0.4 3.84 ± 1.53 3.3 ± 1.2
SPMS (n= 12)
 MSP 3.97 ± 1.47* 2.45 ± 1.0* 2.52 ± 0.56* 1.68 ± 1.3* 1.38 ± 0.65*
 NAWM 6.5 ± 1.9* 3.4 ± 1.5 2.47 ± 0.49 2.6 ± 1.1 2.8 ± 0.7
Control (n= 20) 8.9 ± 1.85 4.56 ± 1.43 2.49 ± 0.6 4.1 ± 1.62 3.2 ± 1.2
X = mean (data are mean concentrations mmol/L) ± standard deviations; SD = standard deviation.
* Statistically signiﬁcant relationships, P< 0.05.
Figure 3 MR images of a 17-year-old female RRMS patient. (A) Axial T2WI. (B) Coronal T2WI. (C) Sagittal T1WI showing left
parietal subcortical MS plaque in all images, the red rectangles indicate the volume of interest (VOI) for MR spectroscopy. (D) Proton
MR spectra of this RRMS patient showing relative preservation of (NAA), elevated Cr, which representing glial cell metabolism and
tissue repair mechanisms and high choline (Cho) representing active inﬂammation (de- and re-myelination).
Table 4 The relation between NAA/Cho ratio in brain and
age at ﬁrst symptoms, disease duration in both groups.
RRMS SPMS
r P-value r P-value
Age at ﬁrst symptoms +0.49 <0.05* 0.485 <0.05*
Disease duration +0.51 <0.05* 0.55 <0.05*
r= correlation coefﬁcient.
* Statistically signiﬁcant relationships, P< 0.05.
262 H.M. Abd El-Rahman et al.ﬁndings, recently, Rigotti et al. (9), who studied whole brain
NAA (WBNAA) in 43 patients with RRMS, found that no
correlation between WBNAA and age of onset, disease dura-
tion nor clinical disability using EDSS score, they also found
that no signiﬁcant difference in WBNAA when comparing
genders or patients receiving treatment versus those who have
not.
Proton MR spectroscopy is a well-established method for
the in vivo investigation of the normal appearing white matter
in patients with MS (29).
Table 5 The relation between NAA/Cho ratio in brain and
clinical disability using EDSS score.
Independent variable Mean correlation eﬃcient SE P-value
EDSS (RRMS) 0.46 0.06 <0.05*
EDSS (SPMS) 0.44 0.045 <0.05*
SE = standard error.
* Statistically signiﬁcant relationships, P< 0.05.
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SPMS, NAA/Cr of MS plaques and NAWM in comparison with
RRMS and healthy controls, most probably reﬂecting different
pathophysiological mechanisms such as axonal damage (31).
Recent surveys underline the potential of MRS in elucidat-
ing widespread tissue damage in NAWM, monitoring various
aspects of inﬂammation in MS, characterizing new, stable and
resolved lesions, predicting the individual clinical course and
monitoring treatment – related effects on myelin repair and
neuroprotection (20,32–34).
Our ﬁnding observed signiﬁcant decrease in NAWM NAA
concentration (and a correspondingly reduced NAA/Cr ratio)
in patients with RRMS and SPMS, our results matched with
previous studies (35–37).
In contrast to our results, Fernando et al. (38) reported
higher absolute concentrations of NAA in NAWM and no sig-
niﬁcant decreased NAA level in patients with deﬁnite MS.
A reduction of NAA levels in MS patients was correlated
with secondary axonal loss in chronic lesions, representing
irreversible damage to the central nervous system (39).
Although the Cr and Cho were increased in RRMS group
in plaques and NAWM, there was not statistically signiﬁcant
when compared to SPMS and the controls. These are consis-
tent with the notion that sustained progression of gliosis and
inﬂammatory changes (demyelination–remyelination). On con-
trary, other authors (40) found in their study signiﬁcant eleva-
tion in Cr in RRMS group compared to controls.
Increased Cho levels in MSP and NAWM in RRMS, as
well as decreased NAA concentrations, is in accordance with
other studies (26,41), presenting inﬂammatory changes and
signiﬁcant axonal damage.
Metabolic ratios are less sensitive than absolute concentra-
tions of individual metabolites (42,43). When comparing
NAA/Cho and NAA/Cr ratios in the lesions, NAWM in
patients versus controls, they were clearly reduced, consistent
with results obtained in previous studies (11,44,45). The obser-
vation is that the magnitude of the reduction varies with the
type and clinical form of the disease. Our comparison of
NAA/Cho and NAA/Cr ratios in patients showed that the
reduction in NAA was more evident in SPMS patients in com-
parison with RRMS and controls.
5. Conclusion
Ourﬁndings support that axonal loss represented bymetabolites
concentrations changes in MRS for both SPMS and RRMS is
important in the development of the disease disability inmultiple
sclerosis. They also provide evidence for axonal loss in normal
appearing white matter in patients with SPMS. Further studies
with larger cohorts of patients are necessary to clarify the signif-
icance of this method in monitoring therapeutic efﬁcacy.References
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